Is Aurora Cannabis Inc. (TSX:ACB) Stock Still Oversold?

Aurora Cannabis (TSX:ACB) (NYSE:ACB) is catching a nice tailwind after a nasty drop through the end of 2018. Is more upside on the way?

| More on:

Marijuana stocks are enjoying a new rally and investors who stayed on the sidelines through the downturn at the end of 2018 are wondering which pot stocks might be the best buys right now.

Let’s take a look at Aurora Cannabis (TSX:ACB)(NYSE:ACB) to see if it deserves to be in your portfolio today.

Acquisitions

Aurora Cannabis has been one of the more aggressive players in the Canadian marijuana market. The company made two major acquisitions in 2018 that consolidated the space and launched Aurora Cannabis into the big leagues among other large players such as Canopy Growth and Tilray.

The deals, which included the $2.5 billion takeover of MedReleaf in July and the $1.1 billion purchase of CanniMed in January, gave Aurora important production capacity and broader geographic coverage for both the Canadian medical marijuana market and the recently launched recreational market.

Aurora is continuing to grow in 2019. The company just announced a $175 million agreement to acquire Whistler Medical Marijuana. The deal adds production facilities in British Columbia, as well as a portfolio of premium products.

Overseas

Aurora also has its sights on a number of international opportunities, including Europe. The company is building a one million square foot greenhouse in Denmark with operations in Germany to serve the growing European medical marijuana market.

Diversified businesses

Aurora’s portfolio of companies includes investments in areas where cannabis products are expected to expand. The company has a 25% interest in Alcanna, the largest private sector alcohol retailer in Canada.

In the cosmetics segment, Aurora has a partnership with Envio Beauty to develop and market hemp seed oil and CBD-based lifestyle products.

The medical opportunities are also in the company’s sights. Aurora has a small ownership position in CTT Pharmaceuticals, which provides innovative drug delivery systems for pain treatment.

Finally, the sale of cannabis edibles is expected to be legalized in Canada at some point in 2019. Aurora has a majority interest in Hempco Food and Fiber, a hemp-based food company with more than a decade of experience in the sector.

Should you buy?

Aurora Cannabis currently trades at $9.60 per share, giving the company a market capitalization of about $9.6 billion. This provides management with the financial clout to continue to grow, and it wouldn’t be a surprise to see Aurora take a run at Aphria or HEXO in 2019.

HEXO, in particular, might be an attractive target, as it would give Aurora a stronger presence in Quebec and also put it in a leadership position in the infused-drinks segment through the Truss partnership with Molson Coors Canada.

The stock is up significantly in the past week, but still sits well below the $15 peak it reached last year. I wouldn’t back up the truck, but Aurora might be an interesting pick today for investors who expect the marijuana sector to take off in the coming years.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned.

More on Investing

Canada national flag waving in wind on clear day
Tech Stocks

Trump Trade: Canadian Stocks to Watch

With Trump returning to the presidency, there are some sectors that could boom in Canada, and others to watch. But…

Read more »

A train passes Morant's curve in Banff National Park in the Canadian Rockies.
Investing

Is Canadian National Railway Worth Buying for its 2.2% Dividend Yield?

Let's dive into whether Canadian National Railway (TSX:CNR) is a top buy for long-term investors at this point in the…

Read more »

nuclear power plant
Energy Stocks

Is Cameco Stock Still a Buy?

Cameco stock recently reported earnings that showed the Westinghouse investment is creating some major costs. But that could change.

Read more »

cloud computing
Dividend Stocks

Insurance Showdown: Better Buy, Great-West Life or Manulife Stock?

GWO stock and MFC stock are two of the top names in insurance, but which holds the better outlook?

Read more »

analyze data
Dividend Stocks

Here’s Why the Average TFSA for Canadians Aged 41 Isn’t Enough

The average TFSA simply isn't enough for most Canadians in their early 40s. Here's how to catch up.

Read more »

A plant grows from coins.
Dividend Stocks

The Smartest Dividend-Growth Stocks to Buy With $1,000 Right Now

New dividend-growth investors should consider CN Rail (TSX:CNR) stock and another top play if they're looking to build wealth over…

Read more »

concept of real estate evaluation
Dividend Stocks

How to Earn a TFSA Paycheque Every Month and Pay No Taxes on It

Canadian REITs can turn your TFSA into a monthly paycheque machine for life. Here's how Morguard North American Residential REIT…

Read more »

Start line on the highway
Investing

2 No-Brainer Growth Stocks to Buy Now With $5,000 and Hold Long Term

Market conditions today are ideal for growth investing, and two rising stocks are no-brainer buys in November.

Read more »